Presentation Title Here in Boldface 36 Point Type

download report

Transcript Presentation Title Here in Boldface 36 Point Type

SAFC Press Briefing
Informex 2012
Gilles Cottier
President of SAFC
February 16, 2012
© 2011 SAFC
Business confidential
SAFC Results for 2011
• $728 Million in Sales
• • 9% Organic Growth
• • 2011 performance driven by our
industrial media and Hitech sales,
which both grew double digits
2
© 2011 SAFC
Business confidential
2012 Highlights
• Grow SAFC business in high
single-digit by leveraging customer
focus, unique manufacturing
capabilities and adjacent services
• SAFC Hitech plant in Taiwan
on-line in Q1 2012
3
© 2011 SAFC
Business confidential
BioReliance Overview
2010 Revenue by Segment
Biologics
Toxicology
Animal Health Services
Global biopharmaceutical services
organization
– Biologics Testing: global market leader
for safety testing and support services for
manufacturers of biologic therapeutics
– Specialized Toxicology Studies: global
market leader for genetic toxicology testing;
leader in transgenic model studies for
oncogenicity
– Animal Health Services: broad spectrum
of laboratory animal diagnostic and
analytical services for health monitoring
and disease outbreak
2010 Revenue: $110M
Global Facilities
Glasgow, Scotland
Stirling, Scotland
Tokyo, Japan
Rockville, USA
Bangalore, India
Total Employees: ~650
BioReliance currently performs testing for ~75% of the top Pharma companies and
~90% of the top Biotech companies in the world.
© 2011 SAFC
4
Business confidential
BioReliance Strategic Rationale and Transaction
Benefits
•Strategic Context
– Combination creates one of the broadest
product and services offerings for the
development and manufacturing of biological
drugs
– Benefits biopharmaceutical customers with a
broad portfolio of product solutions and
services
– Provides platform from which to expand
across laboratory and biological services
Financial Impact
– Purchase price approximately $350 in cash
– Expected to be accretive to growth rate and
earnings in 2012
– Opportunity to drive incremental revenue
growth and returns over time through crossselling, geographic expansion and expansion
of technology platform
5
© 2011 SAFC
Business confidential
Complementary Biologic Development &
Manufacturing Overview
Upstream Bioprocessing
Research
Cell Line
Downstream Bioprocessing
Production Cell
Line (“Cell
Bioreactor
Bank”)
Cloning, cell
Media development,
selection &
upstream process
expansion
optimization (“scale up”)
Raw Material Testing
Unprocessed
Bulk Product
Process
Chromatography
Purified Bulk
Drug
Substance
Final Drug
Product
Formulation
development,
stability testing, fill
& finish
Lot Release & Downstream Process Testing
Raw Material Manufacturing & Supply
Expression System and
Cell Line Development
Contract Biologic Manufacturing
Upstream Process Development
Legend:
BioReliance
Sigma-Aldrich/SAFC
6
© 2011 SAFC
Business confidential